Athos Bousvaros

Appearances

ANTI-TNF IN COMBINATION WITH LOW DOSE METHOTREXATE OUTPERFORMS ANTI-TNF MONOTHERAPY IN PATIENTS WITH PEDIATRIC CROHN'S DISEASE INITIATING ADALIMUMAB BUT NOT INFLIXIMAB
Date
May 8, 2023
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
Presenter
Michael Kappelman
Speakers
David Wohl
Hans Herfarth
University of North Carolina System
Ann Firestine
Jeremy Adler
Steven Steiner
Richard Colletti
KT Park
Andrew Grossman
Anastasia Ivanova
Joseph Galanko
Lourdes Osaba
Kelly Chun
Morris Weinberger
Peter Margolis
Shehzad Saeed
Athos Bousvaros
PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
Date
May 8, 2023
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
Presenter
Jess Kaplan
Speakers
Athos Bousvaros
Dan Turner
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Wendy Komocsar
Amy Larkin
Jordan Johns
Xin Zhang
Cheryl Little
Wallace Crandall
Vipin Arora
Jeffrey Hyams